Ram Ganapathi
Affiliations: | Cleveland State University, Cleveland, OH, United States |
Area:
Analytical Chemistry, Molecular Biology, BiochemistryGoogle:
"Ram Ganapathi"Mean distance: (not calculated yet)
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Ganapathi RN, Ganapathi MK. (2013) Mechanisms regulating resistance to inhibitors of topoisomerase II. Frontiers in Pharmacology. 4: 89 |
Vaziri SA, Tavares EJ, Golshayan AR, et al. (2012) Differing von hippel lindau genotype in paired primary and metastatic tumors in patients with clear cell renal cell carcinoma. Frontiers in Oncology. 2: 51 |
Gillet JP, Calcagno AM, Varma S, et al. (2012) Multidrug resistance-linked gene signature predicts overall survival of patients with primary ovarian serous carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 3197-206 |
Gillet JP, Calcagno AM, Varma S, et al. (2011) Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance. Proceedings of the National Academy of Sciences of the United States of America. 108: 18708-13 |
Bennett KL, Campbell R, Ganapathi S, et al. (2011) Germline and somatic DNA methylation and epigenetic regulation of KILLIN in renal cell carcinoma. Genes, Chromosomes & Cancer. 50: 654-61 |
Grozav AG, Willard BB, Kozuki T, et al. (2011) Tyrosine 656 in topoisomerase IIβ is important for the catalytic activity of the enzyme: Identification based on artifactual +80-Da modification at this site. Proteomics. 11: 829-42 |
Chikamori K, Grozav AG, Kozuki T, et al. (2010) DNA topoisomerase II enzymes as molecular targets for cancer chemotherapy. Current Cancer Drug Targets. 10: 758-71 |
Wang C, Michener CM, Belinson JL, et al. (2010) Role of the 18:1 lysophosphatidic acid-ovarian cancer immunoreactive antigen domain containing 1 (OCIAD1)-integrin axis in generating late-stage ovarian cancer. Molecular Cancer Therapeutics. 9: 1709-18 |
Gillet J, Calcagno AM, Varma S, et al. (2010) Abstract LB-51: Correlation of expression of MDR-associated genes with outcome in primary ovarian serous carcinoma Cancer Research. 70 |
Brady AK, Advani AS, Grabowski D, et al. (2010) Abstract 5431: Histone deacetylase inhibitor (HDAC) panobinostat (LBH589) enhances the antiproliferative effect of a topoisomerase II (topo II) inhibitor in doxorubicin-resistant HL-60 cells, despite high MDR expression Cancer Research. 70: 5431-5431 |